European Journal of Cancer
Volume 46, Issue 1 , Pages 47-55 , January 2010

Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissues

Received 10 September 2009 ,Revised 13 October 2009 ,Accepted 15 October 2009.

References 

  1. Cowherd SM, Espina VA, Petricoin EF, Liotta LA. Proteomic analysis of human breast cancer tissue with laser-capture microdessection and reverse-phase protein microarray. Clin Breast Cancer. 2004;5:385–392
  2. Dhanasekaran DN, Johnson GL. MAPKs: function, regulation, role in cancer and therapeutic targeting. Oncogene. 2007;26:3097–3099
  3. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene. 2007;26:3100–3112
  4. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov. 2003;2:296–313
  5. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–354
  6. Piccart M, Lohrisch C, Di Leo A, Larsimont D. The predictive value of HER2 in breast cancer. Oncology. 2001;61(Suppl 2):73–82
  7. Emens LA. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther. 2005;12:243–253
  8. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712
  9. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  10. Wulfkuhle JD, Speer R, Pierobon M, et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res. 2008;7:1508–1517
  11. Becker KF, Metzger V, Hipp S, Hofler H. Clinical proteomics: new trends for protein microarrays. Curr Med Chem. 2006;13:1831–1837
  12. Becker KF, Schott C, Hipp S, et al. Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J Pathol. 2007;211:370–378
  13. Lim MS, Elenitoba-Johnson KS. Proteomics in pathology research. Lab Invest. 2004;84:1227–1244
  14. Liotta L, Petricoin E. Molecular profiling of human cancer. Nat Rev Genet. 2000;1:48–56
  15. Nirmalan NJ, Harnden P, Selby PJ, Banks RE. Mining the archival formalin-fixed paraffin-embedded tissue proteome: opportunities and challenges. Mol Biosyst. 2008;4:712–720
  16. Kroll J, Becker KF, Kuphal S, Hein R, Hofstadter F, Bosserhoff AK. Isolation of high quality protein samples from punches of formalin fixed and paraffin embedded tissue blocks. Histol Histopathol. 2008;23:391–395
  17. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 2001;20:1981–1989
  18. Chu WS, Liang Q, Liu J, et al. A nondestructive molecule extraction method allowing morphological and molecular analyses using a single tissue section. Lab Invest. 2005;85:1416–1428
  19. Ikeda K, Monden T, Kanoh T, et al. Extraction and analysis of diagnostically useful proteins from formalin-fixed, paraffin-embedded tissue sections. J Histochem Cytochem. 1998;46:397–403
  20. Nirmalan NJ, Harnden P, Selby PJ, Banks RE. Development and validation of a novel protein extraction methodology for quantitation of protein expression in formalin-fixed paraffin-embedded tissues using western blotting. J Pathol. 2009;217:497–506
  21. Chung JY, Lee SJ, Kris Y, Braunschweig T, Traicoff JL, Hewitt SM. A well-based reverse-phase protein array applicable to extracts from formalin-fixed paraffin-embedded tissue. Proteomics Clin Appl. 2008;2:1539–1547
  22. Shi SR, Liu C, Balgley BM, Lee C, Taylor CR. Protein extraction from formalin-fixed, paraffin-embedded tissue sections: quality evaluation by mass spectrometry. J Histochem Cytochem. 2006;54:739–743
  23. Becker KF, Mack H, Schott C, et al. Extraction of phosphorylated proteins from formalin-fixed cancer cells and tissues. TOPATJ. 2008;2:44–52
  24. Becker KF, Schott C, Becker I, Höfler H. Guided protein extraction from formalin-fixed tissues for quantitative multiplex analysis avoids detrimental effects of histological stains. Proteomics Clin Appl. 2008;2:737–743
  25. Addis MF, Tanca A, Pagnozzi D, Crobu S, Fanciulli G, Cossu-Rocca P, et al. Generation of high-quality protein extracts from formalin-fixed, paraffin-embedded tissues. Proteomics. 2009;9:3815–3823
  26. Crockett DK, Lin Z, Vaughn CP, Lim MS, Elenitoba-Johnson KS. Identification of proteins from formalin-fixed paraffin-embedded cells by LC–MS/MS. Lab Invest. 2005;85:1405–1415
  27. Hood BL, Darfler MM, Guiel TG, et al. Proteomic analysis of formalin-fixed prostate cancer tissue. Mol Cell Proteomics. 2005;4:1741–1753
  28. Palmer-Toy DE, Krastins B, Sarracino DA, Nadol JB, Merchant SN. Efficient method for the proteomic analysis of fixed and embedded tissues. J Proteome Res. 2005;4:2404–2411
  29. Sage L. Proteomics gets out of a fix. J Proteome Res. 2005;4:1903–1904
  30. Wulfkuhle JD, Edmiston KH, Liotta LA, Petricoin EF. Technology insight: pharmacoproteomics for cancer–promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol. 2006;3:256–268
  31. Grubb RL, Calvert VS, Wulkuhle JD, et al. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics. 2003;3:2142–2146
  32. Liotta LA, Espina V, Mehta AI, et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell. 2003;3:317–325
  33. Sheehan KM, Calvert VS, Kay EW, et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics. 2005;4:346–355
  34. Espina V, Mehta AI, Winters ME, et al. Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics. 2003;3:2091–2100
  35. Wulfkuhle J, Espina V, Liotta L, Petricoin E. Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur J Cancer. 2004;40:2623–2632
  36. Templin MF, Stoll D, Schrenk M, Traub PC, Vohringer CF, Joos TO. Protein microarray technology. Trends Biotechnol. 2002;20:160–166
  37. Feinberg JG. A ‘microspot’ test for antigens and antibodies. Nature. 1961;192:985–986
  38. Philp AJ, Campbell IG, Leet C, et al. The phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res. 2001;61:7426–7429
  39. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999;21:99–102
  40. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005;6:322–327
  41. Lobke C, Laible M, Rappl C, et al. Contact spotting of protein microarrays coupled with spike-in of normalizer protein permits time-resolved analysis of ERBB receptor signaling. Proteomics. 2008;8:1586–1594
  42. Gulmann C, Sheehan KM, Conroy RM, et al. Quantitative cell signalling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer. J Pathol. 2009;218:514–519
  43. Lu X, Kang Y. Organotropism of breast cancer metastasis. J Mammary Gland Biol Neoplasia. 2007;12:153–162
  44. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–572
  45. Belluco C, Mammano E, Petricoin E, et al. Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. Clin Chim Acta. 2005;357:180–183
  46. Kim JH, Kim MA, Lee HS, Kim WH. Comparative analysis of protein expressions in primary and metastatic gastric carcinomas. Hum Pathol. 2009;40:314–322
  47. van‘t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530–6.
  48. Handschuh G, Candidus S, Luber B, et al. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene. 1999;30:4301–4312

PII: S0959-8049(09)00774-6

doi: 10.1016/j.ejca.2009.10.016

European Journal of Cancer
Volume 46, Issue 1 , Pages 47-55 , January 2010

Article Tools

* Image Usage & Resolution